<DOC>
	<DOCNO>NCT00991718</DOCNO>
	<brief_summary>This open-label , Phase I , single-center , single-dose administration study determine absolute bioavailability , clearance , volume distribution GDC-0449 ( Part A ) determine route excretion extent metabolism GDC-0449 ( Part B ) . Parts A B conduct sequentially , â‰¥ 7 day dose sixth subject Part A dose first subject Part B . In part , 6 healthy female subject non-childbearing potential , 18 65 year age ( inclusive ) , dose .</brief_summary>
	<brief_title>A Study Hedgehog Pathway Inhibitor GDC-0449 Healthy Female Subjects Non-Childbearing Potential</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Female Nonchildbearing potential Body mass index ( BMI ) 18 32 kg/m^2 , inclusive In good health , determine clinically significant finding physical examination , medical history , 12lead ECG , vital sign Negative test drug abuse screening ( include alcohol ) admission clinical research facility ( include alcohol ) Exclusion Criteria History clinical manifestation clinically significant metabolic , hepatic , renal , hematologic , pulmonary , cardiovascular , endocrine , gastrointestinal ( include gastric duodenal ulcer ) , urologic , neurologic , inflammatory , psychiatric disorder , cancer History symptomatic hypotension , idiopathic orthostatic hypotension , autonomousfailure syndrome History severe physical injury , direct impact trauma , neurological trauma within 6 month prior Day 1 History stomach intestinal surgery , stomach disease , resection would potentially alter absorption and/or excretion orally administer drug ( appendectomy , hernia repair , and/or cholecystectomy allow ) History alcoholism , drug abuse , drug addiction ( include soft drug like cannabis product ) Use prescription medications/products , include know enzymeinducing/inhibiting agent , overthecounter medication , nonprescription preparation ( include supplement , vitamin , mineral , phytotherapeutic/herbal/ plantderived preparation , tryptophan , St. John 's wort hypericum perforatumcontaining substance ) within 2 week prior Day 1 , exception hormonereplacement therapy Participation investigational drug study receipt investigational study drug occur within 60 day prior Day 1 within 5 time elimination halflife respective drug ; participation trial involve administration ^1^4Cradiolabeled compound ( ) within 6 month prior Day 1 ; participation two drug trial within 1 year prior Day 1 Receipt vaccination immunization within 1 month prior Day 1 Use nicotinecontaining nicotinereplacement product within 6 month prior Day 1 Consumption alcohol methylxanthinecontaining beverage food Receipt blood product within 2 month prior Day 1 Donation &gt; 100 mL blood within 60 day prior Day 1 ; donation &gt; 1.0 litre blood within 10 month prior Day 1 Irregular defecation pattern , i.e. , less per 2 day within 6 month prior Day 1 ; acute constipation problem within 3 week prior Day 1 ( Part B subject ) Poor peripheral venous access</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>GDC0449</keyword>
</DOC>